Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  2. Department of Physiology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  3. Division of Biomedical Oncology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
  4. Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan
  5. Corresponding author: Ryo Okubo, PhD, MD, Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8551 ([email protected]).
  6. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  7. Department of Psychiatry, Hokkaido University Hospital, Sapporo, Japan
  8. Hokkaido University Hospital Clinical Research & Medical Innovation Center, Sapporo, Japan
  9. Hokkaido University Hospital Clinical Research & Medical Innovation Center, Sapporo, Japan
  10. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  1. Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. PubMed CrossRef
  2. Tanskanen A, Tiihonen J, Taipale H. Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatr Scand. 2018;138(6):492–499. PubMed CrossRef
  3. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627. PubMed CrossRef
  4. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126. PubMed CrossRef
  5. Henderson DC, Vincenzi B, Andrea NV, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2(5):452–464. PubMed CrossRef
  6. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235. PubMed CrossRef
  7. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166–174. PubMed CrossRef
  8. Cao H, Meng Y, Li X, et al. The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting. J Psychiatr Res. 2020;129:265–271. PubMed CrossRef
  9. Godin O, Leboyer M, Schürhoff F, et al; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Predictors of rapid high weight gain in schizophrenia: longitudinal analysis of the French FACE-SZ cohort. J Psychiatr Res. 2017;94:62–69. PubMed CrossRef
  10. Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res. 2012;46(4):540–548. PubMed CrossRef
  11. Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007;191(1):23–29. PubMed CrossRef
  12. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3):171–179. PubMed CrossRef
  13. Hirsch L, Yang J, Bresee L, et al. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40(9):771–781. PubMed CrossRef
  14. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–811. PubMed CrossRef
  15. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry. 2007;68(4):533–541. PubMed CrossRef
  16. Steylen PM, van der Heijden FM, Hoogendijk WJ, et al. Glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study. Diabetes Metab Syndr Obes. 2015;8:57–63. PubMed CrossRef
  17. Mitchell AJ, Vancampfort D, Manu P, et al. Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? a large observational study. PLoS One. 2019;14(9):e0210674. PubMed CrossRef
  18. Lee SY, Park MH, Patkar AA, et al. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):490–496. PubMed CrossRef
  19. Osborn DP, Petersen I, Beckley N, et al. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database. J Psychopharmacol. 2018;32(10):1098–1103. PubMed CrossRef
  20. Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24(1):65–84. PubMed CrossRef
  21. Onrust SV, McClellan K. Perospirone. CNS Drugs. 2001;15(4):329–337, discussion 338. PubMed CrossRef
  22. Kishi T, Ikuta T, Matsunaga S, et al. Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. Neuropsychiatr Dis Treat. 2017;13:1281–1302. PubMed CrossRef
  23. Kusumi I, Arai Y, Okubo R, et al. Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder. BJPsych Open. 2018;4(6):454–460. PubMed CrossRef
  24. Kusumi I, Ito K, Honda M, et al. Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data. Psychiatry Clin Neurosci. 2011;65(4):349–355. PubMed CrossRef
  25. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization; 1992.
  26. Dong M, Zeng L-N, Zhang Q, et al. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. Asian J Psychiatr. 2019;45:74–80. PubMed CrossRef
  27. Yoshio T, Inada T, Uno J, et al. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Hum Psychopharmacol. 2012;27(1):70–75. PubMed CrossRef
  28. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18(4):440–447. PubMed CrossRef
  29. Hirst JA, Stevens RJ, Farmer AJ. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change. PLoS One. 2014;9(3):e92458. PubMed CrossRef
  30. Kameyama M, Okumiya T, Tokuhiro S, et al. Estimation of the hemoglobin glycation rate constant. Sci Rep. 2021;11(1):986. PubMed CrossRef
  31. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997–2004. PubMed CrossRef
  32. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2017.
  33. Kishi T, Matsuda Y, Iwata N. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e88049. PubMed CrossRef
  34. Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208–224. PubMed CrossRef
  35. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. PubMed CrossRef
  36. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. PubMed CrossRef
  37. Rico-Villademoros F, Calandre EP. Risk of bias in observational studies of interventions: the case of antipsychotic-induced diabetes. Lancet Psychiatry. 2016;3(2):103–104. PubMed CrossRef
  38. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. PubMed CrossRef
  39. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1-3):103–110. PubMed CrossRef
  40. Luckhoff H, Phahladira L, Scheffler F, et al. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophr Res. 2019;206:171–176. PubMed CrossRef
  41. Maxwell SE. Sample size and multiple regression analysis. Psychol Methods. 2000;5(4):434–458. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe